251 related articles for article (PubMed ID: 34537409)
1. Repurposing of gastric cancer drugs against COVID-19.
Sonkar C; Doharey PK; Rathore AS; Singh V; Kashyap D; Sahoo AK; Mittal N; Sharma B; Jha HC
Comput Biol Med; 2021 Oct; 137():104826. PubMed ID: 34537409
[TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
3. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
4. Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp.
Murali M; Gowtham HG; Ansari MA; Alomary MN; Alghamdi S; Almehmadi M; Singh SB; Shilpa N; Aiyaz M; Kalegowda N; Ledesma AE; Amruthesh KN
Curr Pharm Des; 2022; 28(12):969-980. PubMed ID: 35796443
[TBL] [Abstract][Full Text] [Related]
5. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
6. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
7.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
8. Structural Homology-Based Drug Repurposing Approach for Targeting NSP12 SARS-CoV-2.
Aljuaid A; Salam A; Almehmadi M; Baammi S; Alshabrmi FM; Allahyani M; Al-Zaydi KM; Izmirly AM; Almaghrabi S; Baothman BK; Shahab M
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431833
[TBL] [Abstract][Full Text] [Related]
9.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
11. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
Ribaudo G; Ongaro A; Oselladore E; Zagotto G; Memo M; Gianoncelli A
J Biomol Struct Dyn; 2022 Feb; 40(3):1101-1108. PubMed ID: 32948103
[TBL] [Abstract][Full Text] [Related]
12. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
[TBL] [Abstract][Full Text] [Related]
13. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
14. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
15. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
16. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
Elfiky AA; Azzam EB; Shafaa MW
Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
[TBL] [Abstract][Full Text] [Related]
17. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
18. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.
Fiorucci D; Milletti E; Orofino F; Brizzi A; Mugnaini C; Corelli F
J Biomol Struct Dyn; 2021 Oct; 39(16):6242-6248. PubMed ID: 32705942
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2.
Dwivedy A; Mariadasse R; Ahmad M; Chakraborty S; Kar D; Tiwari S; Bhattacharyya S; Sonar S; Mani S; Tailor P; Majumdar T; Jeyakanthan J; Biswal BK
PLoS Comput Biol; 2021 Sep; 17(9):e1009384. PubMed ID: 34516563
[TBL] [Abstract][Full Text] [Related]
20.
Doharey PK; Singh V; Gedda MR; Sahoo AK; Varadwaj PK; Sharma B
J Biomol Struct Dyn; 2022 Aug; 40(12):5588-5605. PubMed ID: 33475021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]